These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

704 related articles for article (PubMed ID: 26484727)

  • 1. A meta-analysis of rate ratios for nocturnal confirmed hypoglycaemia with insulin degludec vs. insulin glargine using different definitions for hypoglycaemia.
    Heller S; Mathieu C; Kapur R; Wolden ML; Zinman B
    Diabet Med; 2016 Apr; 33(4):478-87. PubMed ID: 26484727
    [TBL] [Abstract][Full Text] [Related]  

  • 2. (Ultra-)long-acting insulin analogues versus NPH insulin (human isophane insulin) for adults with type 2 diabetes mellitus.
    Semlitsch T; Engler J; Siebenhofer A; Jeitler K; Berghold A; Horvath K
    Cochrane Database Syst Rev; 2020 Nov; 11(11):CD005613. PubMed ID: 33166419
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Day-to-day fasting self-monitored blood glucose variability is associated with risk of hypoglycaemia in insulin-treated patients with type 1 and type 2 diabetes: A post hoc analysis of the SWITCH Trials.
    DeVries JH; Bailey TS; Bhargava A; Gerety G; Gumprecht J; Heller S; Lane W; Wysham CH; Zinman B; Bak BA; Hachmann-Nielsen E; Philis-Tsimikas A
    Diabetes Obes Metab; 2019 Mar; 21(3):622-630. PubMed ID: 30362250
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Insulin degludec results in lower rates of nocturnal hypoglycaemia and fasting plasma glucose vs. insulin glargine: A meta-analysis of seven clinical trials.
    Russell-Jones D; Gall MA; Niemeyer M; Diamant M; Del Prato S
    Nutr Metab Cardiovasc Dis; 2015 Oct; 25(10):898-905. PubMed ID: 26232910
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Rates of hypoglycaemia are lower in patients treated with insulin degludec/liraglutide (IDegLira) than with IDeg or insulin glargine, regardless of the hypoglycaemia definition used.
    Norwood P; Chen R; Jaeckel E; Lingvay I; Jarlov H; Lehmann L; Heller S
    Diabetes Obes Metab; 2017 Nov; 19(11):1562-1569. PubMed ID: 28417535
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical perspectives from the BEGIN and EDITION programmes: Trial-level meta-analyses outcomes with either degludec or glargine 300U/mL vs glargine 100U/mL in T2DM.
    Roussel R; Ritzel R; Boëlle-Le Corfec E; Balkau B; Rosenstock J
    Diabetes Metab; 2018 Nov; 44(5):402-409. PubMed ID: 29548798
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Risk of hypoglycaemia with insulin degludec versus insulin glargine U300 in insulin-treated patients with type 2 diabetes: the randomised, head-to-head CONCLUDE trial.
    Philis-Tsimikas A; Klonoff DC; Khunti K; Bajaj HS; Leiter LA; Hansen MV; Troelsen LN; Ladelund S; Heller S; Pieber TR;
    Diabetologia; 2020 Apr; 63(4):698-710. PubMed ID: 31984443
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Lower rates of hypoglycaemia in older individuals with type 2 diabetes using insulin degludec versus insulin glargine U100: Results from SWITCH 2.
    Heller SR; DeVries JH; Wysham C; Hansen CT; Hansen MV; Frier BM
    Diabetes Obes Metab; 2019 Jul; 21(7):1634-1641. PubMed ID: 30891886
    [TBL] [Abstract][Full Text] [Related]  

  • 9. (Ultra-)long-acting insulin analogues for people with type 1 diabetes mellitus.
    Hemmingsen B; Metzendorf MI; Richter B
    Cochrane Database Syst Rev; 2021 Mar; 3(3):CD013498. PubMed ID: 33662147
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Elderly patients with diabetes experience a lower rate of nocturnal hypoglycaemia with insulin degludec than with insulin glargine: a meta-analysis of phase IIIa trials.
    Sorli C; Warren M; Oyer D; Mersebach H; Johansen T; Gough SC
    Drugs Aging; 2013 Dec; 30(12):1009-18. PubMed ID: 24170235
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of Insulin Degludec vs Insulin Glargine U100 on Hypoglycemia in Patients With Type 2 Diabetes: The SWITCH 2 Randomized Clinical Trial.
    Wysham C; Bhargava A; Chaykin L; de la Rosa R; Handelsman Y; Troelsen LN; Kvist K; Norwood P
    JAMA; 2017 Jul; 318(1):45-56. PubMed ID: 28672317
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of insulin degludec with insulin glargine in insulin-naive subjects with Type 2 diabetes: a 2-year randomized, treat-to-target trial.
    Rodbard HW; Cariou B; Zinman B; Handelsman Y; Philis-Tsimikas A; Skjøth TV; Rana A; Mathieu C;
    Diabet Med; 2013 Nov; 30(11):1298-304. PubMed ID: 23952326
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparative safety and efficacy of insulin degludec with insulin glargine in type 2 and type 1 diabetes: a meta-analysis of randomized controlled trials.
    Zhang XW; Zhang XL; Xu B; Kang LN
    Acta Diabetol; 2018 May; 55(5):429-441. PubMed ID: 29423761
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of Insulin Degludec vs Insulin Glargine U100 on Hypoglycemia in Patients With Type 1 Diabetes: The SWITCH 1 Randomized Clinical Trial.
    Lane W; Bailey TS; Gerety G; Gumprecht J; Philis-Tsimikas A; Hansen CT; Nielsen TSS; Warren M; ;
    JAMA; 2017 Jul; 318(1):33-44. PubMed ID: 28672316
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Insulin degludec improves glycaemic control with lower nocturnal hypoglycaemia risk than insulin glargine in basal-bolus treatment with mealtime insulin aspart in Type 1 diabetes (BEGIN(®) Basal-Bolus Type 1): 2-year results of a randomized clinical trial.
    Bode BW; Buse JB; Fisher M; Garg SK; Marre M; Merker L; Renard E; Russell-Jones DL; Hansen CT; Rana A; Heller SR;
    Diabet Med; 2013 Nov; 30(11):1293-7. PubMed ID: 23710902
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Use of insulin degludec, a new basal insulin with an ultra-long duration of action, in basal-bolus therapy in type 1 and type 2 diabetes.
    Kerlan V; Gouet D; Marre M; Renard É
    Ann Endocrinol (Paris); 2013 Dec; 74(5-6):487-90. PubMed ID: 23978337
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Insulin degludec, an ultra-longacting basal insulin, versus insulin glargine in basal-bolus treatment with mealtime insulin aspart in type 1 diabetes (BEGIN Basal-Bolus Type 1): a phase 3, randomised, open-label, treat-to-target non-inferiority trial.
    Heller S; Buse J; Fisher M; Garg S; Marre M; Merker L; Renard E; Russell-Jones D; Philotheou A; Francisco AM; Pei H; Bode B;
    Lancet; 2012 Apr; 379(9825):1489-97. PubMed ID: 22521071
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The effect of insulin degludec on risk of symptomatic nocturnal hypoglycaemia in adults with type 1 diabetes and high risk of nocturnal severe hypoglycaemia (the HypoDeg trial): study rationale and design.
    Agesen RM; Alibegovic AC; Andersen HU; Beck-Nielsen H; Gustenhoff P; Hansen TK; Hedetoft C; Jensen T; Juhl CB; Lerche SS; Nørgaard K; Parving HH; Tarnow L; Thorsteinsson B; Pedersen-Bjergaard U
    BMC Endocr Disord; 2019 Jul; 19(1):78. PubMed ID: 31337371
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Severe hypoglycaemia in adults with insulin-treated diabetes: impact on healthcare resources.
    Heller SR; Frier BM; Hersløv ML; Gundgaard J; Gough SC
    Diabet Med; 2016 Apr; 33(4):471-7. PubMed ID: 26179360
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical benefits of switching to insulin degludec irrespective of previous basal insulin therapy in people with Type 1 or Type 2 diabetes: evidence from a European, multicentre, retrospective, non-interventional study (EU-TREAT).
    Knudsen ST; Lapolla A; Schultes B; Tentolouris N; Catarig AM; Wolden ML; Siegmund T
    Diabet Med; 2019 Jul; 36(7):868-877. PubMed ID: 31001865
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 36.